1-20 of 42
Enriqueta Felip
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract CT051: SKYSCRAPER-01: A phase III, randomized trial of tiragolumab (tira) + atezolizumab (atezo) versus placebo (pbo) + atezo in patients (pts) with previously-untreated PD-L1-high, locally advanced unresectable/metastatic NSCLC

Free
Solange Peters, Roy Herbst, Hidehito Horinouchi, Luis Paz-Ares, Melissa Johnson, Benjamin Solomon, Mahmut Gumus, Mustafa Erman, Igor Bondarenko, Dong-Wan Kim, Enriqueta Felip, Alessandro Morabito, Maciej Bryl, Raymond Meng, Chipman Stroud, Palak Kundu, Xiaohui Wen, Namrata Patil, Meilin Huang, Byoung Chul Cho
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_2): CT051.
https://doi.org/10.1158/1538-7445.AM2025-CT051
Published: 25 April 2025
View articletitled, Abstract CT051: SKYSCRAPER-01: A phase III, randomized trial of tiragolumab (tira) + atezolizumab (atezo) versus placebo (pbo) + atezo in patients (pts) with previously-untreated PD-L1-high, locally advanced unresectable/metastatic NSCLC
Journal Articles

Abstract LB399: Trop-2 expression and association with efficacy in patients treated with sacituzumab govitecan + pembrolizumab +/- carboplatin in the EVOKE-02 study of non-small cell lung cancer

Free
Jyoti D. Patel, Marianna Zavodovskaya, Byoung Chul Cho, Martin Reck, Jhanelle E. Gray, Noemí Reguart, Enriqueta Felip, Joel W. Neal, Kai-Wen Lin, Juliane M. Jürgensmeier, Sabeen Mekan, Farnoush Safavi, Michael Chisamore, Edward Garon
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_2): LB399.
https://doi.org/10.1158/1538-7445.AM2025-LB399
Published: 25 April 2025
View articletitled, Abstract LB399: Trop-2 expression and association with efficacy in patients treated with sacituzumab govitecan + pembrolizumab +/- carboplatin in the EVOKE-02 study of non-small cell lung cancer
Journal Articles

Abstract CT137: Initial results from a phase 1 study of an A2a receptor antagonist, administered as monotherapy and in combination with anti-PD1 therapy in patients with advanced non-small cell lung cancer

Free
Prantesh Jain, Alexander Spira, Seehoon Lee, Byoung Chul Cho, Enriqueta Felip, Andres Aguilar, Sarah Gordon, Sebastian Ochsenreither, Thomas Wehler, Amanda McGillivray, Ariel Chen, Raja Venkatasubramanian, Rajesh Bandekar, Shu Jin, Rosa Martín-Pérez, Aisha Nasreen Hasan, Brian Henick
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_2): CT137.
https://doi.org/10.1158/1538-7445.AM2025-CT137
Published: 25 April 2025
View articletitled, Abstract CT137: Initial results from a phase 1 study of an A2a receptor antagonist, administered as monotherapy and in combination with anti-PD1 therapy in patients with advanced non-small cell lung cancer
Journal Articles

Abstract 7147: Ultra-high throughput single-nuclei RNAs sequencing of malignant pleural mesothelioma samples in the BEAT-MESO clinical trial

Free
Daria Buszta, Maxim Norkin, Jonathan Bac, Sanjay Popat, Anthony Pope, Riyaz Shah, Toby Talbot, Julia Giner, Wold-Dieter Janthur, Ernest Nadal, Annamaria Catino, David Gilligan, Amy Roy, Zoi Tsourti, Patrick Vagenknecht, Georgia Dimopoulou, Roswitha Kammler, Stephen P. Finn, Enriqueta Felip, Solange Peters, Rolf Stahel, Raphael Gottardo, Krisztian Homicsko
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_1): 7147.
https://doi.org/10.1158/1538-7445.AM2025-7147
Published: 21 April 2025
View articletitled, Abstract 7147: Ultra-high throughput single-nuclei RNAs sequencing of malignant pleural mesothelioma samples in the BEAT-MESO clinical trial
Journal Articles

Abstract CT239: IMpower010: Updated overall survival and safety results from Asian patients in a Phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA NSCLC

Free
Jie Wang, Yun Fan, Jian Fang, Jianxing He, Yunpeng Liu, Min Tao, Nasser Altorki, Enriqueta Felip, Heather Wakelee, Eric Vallieres, Rossella Belleli, Virginia McNally, Elizabeth Bennett, Barbara J. Gitlitz, Caicun Zhou
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): CT239.
https://doi.org/10.1158/1538-7445.AM2024-CT239
Published: 05 April 2024
View articletitled, Abstract CT239: IMpower010: Updated overall survival and safety results from Asian patients in a Phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA NSCLC
Journal Articles

Abstract CT282: MK-2870-004: A phase 3 study of MK-2870 (SKB264) versus chemotherapy for previously treated advanced or metastatic nonsquamous non-small-cell lung cancer (NSCLC) with EGFR mutations or other genomic alterations

Free
Federico Cappuzzo, Edward B. Garon, Myung-Ju Ahn, Shun Lu, Terufumi Kato, Enriqueta Felip, Parneet Cheema, Nicolas Girard, Mark Shamoun, Guoqing Wang, Bin Zhao, Rina Hui
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): CT282.
https://doi.org/10.1158/1538-7445.AM2024-CT282
Published: 05 April 2024
View articletitled, Abstract CT282: MK-2870-004: A phase 3 study of MK-2870 (SKB264) versus chemotherapy for previously treated advanced or metastatic nonsquamous non-small-cell lung cancer (NSCLC) with EGFR mutations or other genomic alterations
Journal Articles

Abstract CT280: FURVENT, Phase 3 trial testing furmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertions (FURMO-004)

Free
Alexander Spira, Byoung Chul Cho, Enriqueta Felip, Edward Garon, Koichi Goto, Melissa Lynne Johnson, Natasha B. Leighl, Antonio Passaro, David Planchard, Sanjay Popat, James Yang, Xiaoqian Lu, Yong Jiang, Jack Huang, Morgan Lam, Marcin Kowanetz, Shirley Wang, John Le, Jerry Hsu, Caicun Zhou
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): CT280.
https://doi.org/10.1158/1538-7445.AM2024-CT280
Published: 05 April 2024
View articletitled, Abstract CT280: FURVENT, Phase 3 trial testing furmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertions (FURMO-004)
Journal Articles

Abstract LB107: Association of circulating free DNA (cfDNA) maximum variant allele frequency (mVAF) levels with clinical outcomes in patients (pts) with metastatic nonsquamous non-small cell lung cancer (NSCLC) treated with pembrolizumab (pembro) + chemotherapy (chemo) in the phase 2 KEYNOTE-782 trial

Free
Jair Bar, Emilio Esteban, Delvys Rodríguez-Abreu, Santiago Ponce-Aix, Zsuzsanna Szalai, Enriqueta Felip, Maya Gottfried, Mariano Provencio Pulla, Andrew Robinson, Andrea Fülöp, Suman Bannur Rao, D. Ross Camidge, Giovanna Speranza, Nathan Hunkapiller, Robert McDaniel, Byoungsok Jung, David Burkhardt, Ruth Mauntz, Cai Chen, Carol Pena, Razvan Cristescu, Elisha J. Dettman, Steven M. Townson, Julie Kobie, Tibor Csőszi
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): LB107.
https://doi.org/10.1158/1538-7445.AM2024-LB107
Published: 05 April 2024
View articletitled, Abstract LB107: Association of circulating free DNA (cfDNA) maximum variant allele frequency (mVAF) levels with clinical outcomes in patients (pts) with metastatic nonsquamous non-small cell lung cancer (NSCLC) treated with pembrolizumab (pembro) + chemotherapy (chemo) in the phase 2 KEYNOTE-782 trial
Journal Articles

PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells

Available to Purchase
Francisco Exposito, Miriam Redrado, Maeva Houry, Katherine Hastings, Magdalena Molero-Abraham, Teresa Lozano, Jose Luis Solorzano, Julian Sanz-Ortega, Vera Adradas, Ramon Amat, Esther Redin, Sergio Leon, Naroa Legarra, Javier Garcia, Diego Serrano, Karmele Valencia, Camila Robles-Oteiza, Giorgia Foggetti, Nerea Otegui, Enriqueta Felip, Juan J. Lasarte, Luis Paz-Ares, Jon Zugazagoitia, Katerina Politi, Luis Montuenga, Alfonso Calvo
Journal: Cancer Research
Cancer Res (2023) 83 (15): 2513–2526.
https://doi.org/10.1158/0008-5472.CAN-22-3023
Published: 01 August 2023
View articletitled, PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
Open the PDF for PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells in another window
Includes: Supplementary data
Journal Articles

Abstract CT216: Response to first-line (1L) pembrolizumab (pembro) + chemotherapy (chemo) in non-small cell lung cancer (NSCLC) by blood tumor mutational burden (bTMB): the phase 2 KEYNOTE-782 trial

Free
Jair Bar, Emilio Esteban, Delvys Rodríguez-Abreu, Santiago Ponce Aix, Zsuzsanna Szalai, Enriqueta Felip, Maya Gottfried, Mariano Provencio Pulla, Andrew Robinson, Andrea Fülöp, Suman B. Rao, D. Ross Camidge, Giovanna Speranza, Steven M. Townson, Julie Kobie, Mark Ayers, Elisha J. Dettman, Robert McDaniel, Byoungsok Jung, David Burkhardt, Ruth Mauntz, Tibor Csőszi
Journal: Cancer Research
Cancer Res (2023) 83 (8_Supplement): CT216.
https://doi.org/10.1158/1538-7445.AM2023-CT216
Published: 14 April 2023
View articletitled, Abstract CT216: Response to first-line (1L) pembrolizumab (pembro) + chemotherapy (chemo) in non-small cell lung cancer (NSCLC) by blood tumor mutational burden (bTMB): the phase 2 KEYNOTE-782 trial
Journal Articles

Abstract CT048: A Phase II trial of JDQ443 in KRAS G12C-mutated NSCLC with PD-L1 expression <1% or PD-L1 expression≥1% and an STK11 co-mutation

Free
Colin R. Lindsay, Daniel Tan, Shweta Malhotra, Rafael Caparica, Aislyn D. Boran, Gilberto Castro, Sabine Glaser, Rajwanth R. Veluswamy, Enriqueta Felip
Journal: Cancer Research
Cancer Res (2023) 83 (8_Supplement): CT048.
https://doi.org/10.1158/1538-7445.AM2023-CT048
Published: 14 April 2023
View articletitled, Abstract CT048: A Phase II trial of JDQ443 in KRAS G12C-mutated NSCLC with PD-L1 expression &lt;1% or PD-L1 expression≥1% and an STK11 co-mutation
Journal Articles

Abstract 5712: Anti-TIGIT antibody tiragolumab leverages myeloid cells and regulatory T cells to improve PD-L1 checkpoint blockade

Free
Namrata S. Patil, Shyam Srivats, Yoonha Choi, Xiangnan Guan, Barzin Nabet, Lisa McGinnis, Eugene Chiang, Alexis Dunkle, Bill O’Gorman, Patrick S. Chang, Ruozhen Hu, John Silva, Joy Han, Amelia Au-Yeung, Chikara Takahashi, Nandini Molden, Pallavi Daggumati, Wendy Connolly, Melissa Johnson, Delvys Rodriguez Abreu, Byoung Chul Cho, Antoine Italiano, Ignacio Gil-Bazo, Enriqueta Felip, Ira Mellman, Raymond Meng, Sanjeev Mariathasan, Robert Johnston, David S. Shames
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 5712.
https://doi.org/10.1158/1538-7445.AM2023-5712
Published: 04 April 2023
View articletitled, Abstract 5712: Anti-TIGIT antibody tiragolumab leverages myeloid cells and regulatory T cells to improve PD-L1 checkpoint blockade
Journal Articles

Abstract 1124: PTEN loss confers resistance to anti-PD-1 therapy in NSCLC by increasing tumor infiltration of T regulatory cells

Free
Francisco Exposito, Miriam Redrado, Maeva Houry, Katherine Hastings, Magdalena Molero-Abraham, Teresa Lozano, Jose L. Solorzano, Julian Sanz Ortega, Vera Andradas, Ramon Amat, Esther Redin, Sergio Leon, Naroa Legarra, Javier García, Diego Serrano, Karmele Valencia, Camila Robles-Oteiza, Giorgia Foggetti, Enriqueta Felip, Juan J. Lasarte, Luis Paz-Ares, Jon Zugazagoitia, Katerina Politi, Luis M Montuenga, Alfonso Calvo
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 1124.
https://doi.org/10.1158/1538-7445.AM2023-1124
Published: 04 April 2023
View articletitled, Abstract 1124: PTEN loss confers resistance to anti-PD-1 therapy in NSCLC by increasing tumor infiltration of T regulatory cells
Journal Articles

Abstract 3989: DSTYK inhibition sensitizes lung cancer cells to immunotherapy by collapsing cytoprotective autophagy and destroying mitochondrial wellness

Free
Karmele Valencia, Mirari Echepare, Andrea Pasquier, Alvaro Teijeira, Cristina Bertolo, Cristina Sainz, Graziella Bosco, Roman K. Thomas, Jackeline Agorreta, Jose Maria Lopez-Picazo, Joan Frigola, Ramon Amat, Alfonso Calvo, Enriqueta Felip, Luis M. Montuenga
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 3989.
https://doi.org/10.1158/1538-7445.AM2022-3989
Published: 15 June 2022
View articletitled, Abstract 3989: DSTYK inhibition sensitizes lung cancer cells to immunotherapy by collapsing cytoprotective autophagy and destroying mitochondrial wellness
Journal Articles

Abstract CT536: Tepotinib efficacy and safety in patients with MET exon 14 (METex14) skipping NSCLC

Free
Marina C. Garassino, Xiuning Le, Wade T. Iam, Enriqueta Felip, Hiroshi Sakai, Remi Veillon, Egbert F. Smit, Julien Mazieres, Jo Raskin, Alexis B. Cortot, Karin Berghoff, Rolf Bruns, Gordon Otto, Paul K. Paik
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): CT536.
https://doi.org/10.1158/1538-7445.AM2022-CT536
Published: 15 June 2022
View articletitled, Abstract CT536: Tepotinib efficacy and safety in patients with MET exon 14 (METex14) skipping NSCLC
Journal Articles

Abstract CT033: KontRASt-01: A phase Ib/II, dose-escalation study of JDQ443 in patients (pts) with advanced, KRAS G12C-mutated solid tumors

Free
Daniel S. Tan, Toshio Shimizu, Benjamin Solomon, Rebecca S. Heist, Martin Schuler, Maria J. De Miguel Luken, Anas Gazzah, Martin Wermke, Christophe Dooms, Herbert H. Loong, Neeltje Steeghs, Enriqueta Felip, Conor E. Steuer, Eric van Cutsem, Ross A. Soo, Ashley C. Jaeger, Jaeyeon Kim, Kun Xu, Xueying Chen, Xiaoming Cui, Heather Burks, Anna Farago, Philippe A. Cassier
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): CT033.
https://doi.org/10.1158/1538-7445.AM2022-CT033
Published: 15 June 2022
View articletitled, Abstract CT033: KontRASt-01: A phase Ib/II, dose-escalation study of JDQ443 in patients (pts) with advanced, KRAS G12C-mutated solid tumors
Journal Articles

Abstract CT012: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment for resectable (IB-IIIA) non-small cell lung cancer (NSCLC): Event-free survival (EFS) results from the phase 3 CheckMate 816 trial

Free
Nicolas Girard, Jonathan Spicer, Mariano Provencio, Shun Lu, Stephen Broderick, Mark M. Awad, Tetsuya Mitsudomi, Keith Kerr, Julie Brahmer, Scott J. Swanson, Enriqueta Felip, Changli Wang, Gene B. Saylors, Ke-Neng Chen, Fumihiro Tanaka, Moishe Liberman, Cecile Dorange, Javed Mahmood, Junliang Cai, Patrick M. Forde
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): CT012.
https://doi.org/10.1158/1538-7445.AM2022-CT012
Published: 15 June 2022
View articletitled, Abstract CT012: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment for resectable (IB-IIIA) non-small cell lung cancer (NSCLC): Event-free survival (EFS) results from the phase 3 CheckMate 816 trial
Journal Articles

Abstract CT016: MEDI5752, a novel PD-1/CTLA-4 bispecific checkpoint inhibitor for advanced solid tumors: First-in-human study

Free
Ben Tran, Mark Voskoboynik, Sang-We Kim, Charlotte Lemech, Enric Carcereny, Sun Young Rha, Myung-Ju Ahn, Enriqueta Felip, Ki H. Lee, Eduardo C. Alvarez, James Chih-Hsin Yang, Paolo A. Ascierto, Mariano P. Pulla, Dan Freeman, Xuyang Song, Shelby D. Gainer, Patrick Mitchell, Ikbel Achour, Deepa S. Subramaniam, Seock-Ah Im
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): CT016.
https://doi.org/10.1158/1538-7445.AM2022-CT016
Published: 15 June 2022
View articletitled, Abstract CT016: MEDI5752, a novel PD-1/CTLA-4 bispecific checkpoint inhibitor for advanced solid tumors: First-in-human study
Journal Articles

Abstract CT037: Canakinumab in combination with first-line (1L) pembrolizumab plus chemotherapy for advanced non-small cell lung cancer (aNSCLC): Results from the CANOPY-1 phase 3 trial

Free
Daniel S. Tan, Enriqueta Felip, Gilberto Castro, Benjamin J. Solomon, Alastair Greystoke, Byoungchul Cho, Manuel Cobo, Tae Min Kim, Sandip Ganguly, Enric Carcereny, Luis Paz-Ares, Jaafar Bennouna, Marina Garassino, Michael Schenker, Sang-We Kim, Bijoyesh Mookerje, Vanessa Q. Passos, Stephanie Deudon, Bharani Dharan, Yuanbo Song, Rafael Caparica, Bruce E. Johnson
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): CT037.
https://doi.org/10.1158/1538-7445.AM2022-CT037
Published: 15 June 2022
View articletitled, Abstract CT037: Canakinumab in combination with first-line (1L) pembrolizumab plus chemotherapy for advanced non-small cell lung cancer (aNSCLC): Results from the CANOPY-1 phase 3 trial
Journal Articles

Abstract CT223: Updated efficacy and safety from the phase 3 CROWN study of first-line lorlatinib vs crizotinib in advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)

Free
Benjamin Solomon, Todd Bauer, Tony Mok, Geoffrey Liu, Julien Mazieres, Filippo de Marinis, Yasushi Goto, Dong-Wan Kim, Yi-Long Wu, Mikhail Dvorkin, Jacek Jassem, Froylán López-López, Ross Soo, Anna Polli, Elisa Dall'O, Laura Iadeluca, Francesca Toffalorio, Enriqueta Felip
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): CT223.
https://doi.org/10.1158/1538-7445.AM2022-CT223
Published: 15 June 2022
View articletitled, Abstract CT223: Updated efficacy and safety from the phase 3 CROWN study of first-line lorlatinib vs crizotinib in advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)